Genetic Cancer Biomarkers - Global Strategic Business Report

The global market for Genetic Cancer Biomarkers was valued at US$5.2 Billion in 2024 and is projected to reach US$13.9 Billion by 2030, growing at a CAGR of 17.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Genetic Cancer Biomarkers market.

Global Genetic Cancer Biomarkers Market - Key Trends & Drivers Summarized

Why Are Genetic Biomarkers Gaining Importance in Cancer Diagnosis and Treatment?

Genetic cancer biomarkers are DNA or RNA-based indicators that reveal the presence, progression, or treatment responsiveness of tumors. These biomarkers are used for early detection, prognosis evaluation, therapy selection, and recurrence monitoring. As cancer research evolves toward personalized treatment strategies, genetic biomarkers play an essential role in matching therapies to individual tumor profiles. This approach reduces trial-and-error in drug administration and improves treatment outcomes.

Applications range from identifying inherited cancer risk to detecting acquired mutations within tumors. Biomarkers such as BRCA1/2, EGFR, KRAS, and BRAF help guide therapeutic decisions in breast, lung, colorectal, and melanoma cases. Non-invasive sampling techniques, including liquid biopsies, are improving the accessibility of genetic testing, enabling more frequent monitoring. The growing adoption of companion diagnostics by oncology specialists is further establishing the role of genetic biomarkers in clinical practice.

How Are Technological Advances Enhancing Biomarker Detection and Interpretation?

High-throughput sequencing technologies such as next-generation sequencing (NGS) and digital PCR are enabling faster, more accurate identification of cancer-associated mutations. These tools allow simultaneous analysis of multiple genes with high sensitivity, even from small or degraded samples. Computational platforms now support variant calling, mutation annotation, and predictive analytics, improving biomarker interpretation and clinical decision-making.

Integration of artificial intelligence and machine learning is refining biomarker classification by analyzing genomic patterns across large patient cohorts. Cloud-based platforms enable sharing of anonymized genomic data for research and therapeutic development. Laboratory-developed tests and FDA-approved panels are expanding the range of actionable biomarkers for solid tumors and hematologic malignancies. As molecular diagnostics continue to evolve, bioinformatics and data integration are becoming essential to managing the increasing complexity of cancer genomics.

Where Are Genetic Biomarkers Being Adopted Most Widely in Oncology?

Hospitals, cancer centers, and reference laboratories are the primary users of genetic cancer biomarker testing. In high-income countries, biomarker testing is integrated into standard care pathways for several cancers, including non-small cell lung cancer, colorectal cancer, and breast cancer. Testing is used to assess therapy eligibility, predict resistance, and monitor minimal residual disease. Oncology practices in emerging markets are also adopting biomarker testing through partnerships with diagnostic labs and pharmaceutical companies.

Biopharmaceutical firms rely on biomarkers for patient stratification in clinical trials, especially for immunotherapy and targeted therapies. Precision oncology programs and cancer registries use genetic profiling to track mutation prevalence and treatment outcomes. As access to NGS platforms and genetic counseling improves, community oncology practices are incorporating biomarker testing into routine workflows. Adoption is growing across both academic and commercial segments of cancer care.

What Is Driving Growth in the Genetic Cancer Biomarkers Market?

Growth in the genetic cancer biomarkers market is driven by several factors related to molecular diagnostics integration, therapy personalization, and sequencing accessibility. Increased use of biomarker-guided treatment in oncology care is supporting demand for comprehensive mutation panels and companion diagnostics. Advances in NGS, liquid biopsy, and digital PCR are enabling faster, minimally invasive, and highly sensitive mutation detection. Growth is also supported by the development of targeted drugs that require biomarker identification, expansion of oncology-focused clinical trials, and reimbursement progress for genetic testing. As precision medicine continues to transform cancer care, genetic biomarkers are central to diagnostic innovation and therapeutic alignment.

Scope of the Report

The report analyzes the Genetic Cancer Biomarkers market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below:

• Segments: Technology (OMICS, Bioinformatics, Other Technologies); Cancer Type (Breast Cancer, Prostate Cancer, Leukemia, Other Cancer Types).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the OMICS segment, which is expected to reach US$6.6 Billion by 2030 with a CAGR of a 15.5%. The Bioinformatics segment is also set to grow at 20.2% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $1.4 Billion in 2024, and China, forecasted to grow at an impressive 22.9% CAGR to reach $3.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Genetic Cancer Biomarkers Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Genetic Cancer Biomarkers Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Genetic Cancer Biomarkers Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, Agilent Technologies, Amgen Inc., Bio-Rad Laboratories, Bio-Techne Corporation and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 36 companies featured in this Genetic Cancer Biomarkers market report include:

• Abbott Laboratories
• Agilent Technologies
• Amgen Inc.
• Bio-Rad Laboratories
• Bio-Techne Corporation
• BGI Genomics
• Caris Life Sciences
• Danaher Corporation (Cepheid, Beckman Coulter)
• Exact Sciences Corporation
• Foundation Medicine (Roche)
• Fulgent Genetics
• Guardant Health
• Illumina, Inc.
• Invitae Corporation
• Myriad Genetics
• NeoGenomics Laboratories
• Qiagen N.V.
• Roche Diagnostics
• Thermo Fisher Scientific
• Veracyte, Inc.

This edition integrates the latest global trade and economic shifts into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis from 2015 to 2023.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025 (E), competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.